MoneyWorks4Me

Cadila Healthcare informs about press release

13 Dec 2021 Evaluate

Cadila Healthcare has informed that it enclosed a copy of press release dated December 13, 2021 titled ‘Zydus to begin Phase II (a) clinical trial of ZYIL1, a novel oral NLRP3 inflammasome inhibitor in patients with Cryopyrin-Associated Periodic Syndrome (CAPS) in Australia’.

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences Share Price

1110.70 5.70 (0.52%)
20-Aug-2026 09:43 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1898.80
Dr. Reddys Labs. 1174.30
Cipla 1430.05
Lupin 2224.90
Zydus Lifesciences 1110.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: